ReviewIntractable & rare diseases research2026
Foods for special medical purposes for the dietary therapy of rare diseases: Current status and future prospects.
Review in Intractable & rare diseases research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foods for special medical purposes (FSMPs) is a type of products that provides targeted nutritional support for specific diseases or physiological conditions. Compared with conventional dietary therapy, FSMPs are more targeted, safer, and applicable in clinic. When FSMPs are used to treat rare diseases, their core principle is to bypass or alleviate metabolic disorders. With the increasing recognition of clinical treatment effectiveness and the growing demand from patients, the types and market scale of commercial rare disease FSMPs continue to expand. However, there are currently no article summarized and analyzed the characteristics of diverse commercial products. Based on this, this review collected and collated the vast majority of commercial rare disease FSMPs in the global market, and summarized the characteristics of these products by categorizing them into protein substitutes, nutritional modules, ketogenic diets (KDs), and special low protein foods (SLPFs). Following the comprehensive analysis of the global commercial rare disease FSMPs landscape, this review shifted focus to China and provided suggestions from product diversity, technological innovation, and policy optimization. It aims to offer available suggestions and references for the healthy development of rare disease FSMPs in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.